Triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer (MBC): latest results of an international phase II trial

被引：0
|
作者：
Chan, A. [1 ]
Ganju, V. [2 ]
Becquart, D. [3 ]
Conte, P. F. [4 ]
Petruzelka, L. [5 ]
Perrot, O. [6 ]
Villanova, G. [6 ]
Tubiana-Mathieu, N. [7 ]
机构：
[1] Mt Hosp, Perth, WA, Australia
[2] Frankston Hosp, Frankston, Australia
[3] AZ Middlelheim, Antwerp, Belgium
[4] Policlin Modena, Modena, Italy
[5] Gen Teaching Hosp, Prague, Czech Republic
[6] Inst Rech Pierre Fabre, Boulogne, France
[7] CHU Dupuytren, Limoges, France
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70886-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2124
引用
收藏
页码：221 / 222
页数：2
相关论文
共 50 条
  • [31] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Onder Tonyali
    Mustafa Benekli
    Veli Berk
    Ugur Coskun
    Metin Ozkan
    Ramazan Yildiz
    Emel Ucgul
    Alper Sevinc
    Dogan Uncu
    Umut Demirci
    Suleyman Buyukberber
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 981 - 986
  • [32] Efficacy and toxicity of Trastuzumab and Paclitaxel plus Capecitabine in the first-line treatment of HER2-positive metastatic breast cancer
    Tonyali, Onder
    Benekli, Mustafa
    Berk, Veli
    Coskun, Ugur
    Ozkan, Metin
    Yildiz, Ramazan
    Ucgul, Emel
    Sevinc, Alper
    Uncu, Dogan
    Demirci, Umut
    Buyukberber, Suleyman
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (06) : 981 - 986
  • [33] Updated analysis of an international phase II study evaluating an all-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer (MBC)
    Tubiana-Mathieu, N.
    Bougnoux, P.
    Becquart, D.
    Chan, A.
    Majois, F.
    Espie, M.
    Perrot, O.
    Villanova, G.
    Conte, P. F.
    EJC SUPPLEMENTS, 2007, 5 (04): : 223 - 223
  • [34] Phase II study of an all-oral combination of oral vinorelbine (NVBo) and capecitabine (X) in HER2-negative metastatic breast cancer (MBC): First results of an international phase II trial.
    Tubiana-Mathieu, N.
    Bougnoux, P.
    Becquart, D.
    Chan, A.
    Majois, F.
    Espie, M.
    Aubert, D.
    Bourlard, T.
    Villanova, G.
    Conte, P-F
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S280 - S280
  • [35] Interim safety of pertuzumab in combination with trastuzumab and vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E.
    Lopez-Vega, J. M.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S178 - S179
  • [36] Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer
    Martin, Miguel
    Makhson, Anatoly
    Gligorov, Joseph
    Lichinitser, Mikhail
    Lluch, Ana
    Semiglazov, Vladimir
    Scotto, Nana
    Mitchell, Lada
    Tjulandin, Sergei
    ONCOLOGIST, 2012, 17 (04): : 469 - 475
  • [37] Triple combination of 3-weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer (MBC): an active and well-tolerated regimen that allows patient compliance
    Palumbo, R.
    Bernardo, A.
    Strada, M. R.
    Poggi, G.
    Teragni, C.
    Amatu, A.
    Frascaroli, M.
    Montagna, B.
    Sottotetti, F.
    Bernardo, G.
    EJC SUPPLEMENTS, 2009, 7 (02): : 285 - 285
  • [38] Phase II study with dose finding of Oral Vinorelbine in combination with Capecitabine as first-line chemotherapy of Metastatic Breast Cancer (MBC): Preliminary results of the phase II part of the study
    不详
    EJC SUPPLEMENTS, 2006, 4 (02): : 167 - 167
  • [39] A phase II trial of capecitabine and vinorelbine as first-line treatment in patients with metastatic breast cancer (BC)
    Palumbo, Raffaella
    Bernardo, Antonio
    Strada, Maria Rosa
    Poggi, Guido
    Delmonte, Angelo
    Teragni, Cristina
    Frascaroli, Mara
    Bernardo, Giovanni
    ANNALS OF ONCOLOGY, 2006, 17 : 75 - 75
  • [40] First results of a phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of HER2+LA/MBC.
    Tjulandin, S.
    Makhson, A.
    Gligorov, J.
    Lichinitser, M.
    Lluch, A.
    Semiglazov, V.
    Scotto, N.
    Mitchell, L.
    Martin, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345